Figure 2
From: Development of a peptide-siRNA nanocomplex targeting NF- κB for efficient cartilage delivery
p5RHH-p65 siRNA NP attenuates chondrocyte apoptosis and maintains cartilage homeostasis. IL-1β-treated human cartilage explants were incubated with p5RHH-p65 siRNA NP (p65 NP) or scrambled siRNA NP (scram NP) as detailed above. (A) Immunofluorescence of cleaved PARP (cPARP) (green) in cartilage sections at day 7. (B) Number of cells with nuclear cPARP at 48 h and (C) at 14 days after IL-1 β exposure and NP treatment. (D) Immunofluorescence of LC3 in cartilage sections without and with IL-1β exposure at day 7. (E) Mean fluorescence of LC3 per chondrocyte after exposure to IL-1β at day 7 and (F) at different time points after exposure to NP treatment. Mean reflects analysis of 5–8 areas, each including 3–6 cells, n = 3–5 individual cartilage explants were analyzed per treatment per time point. *P < 0.05, **P < 0.01, ***P < 0.001; n.s. not significant. COL2 (red), type II collagen; DAPI (blue) stained nuclei.
